Shanghai Changzheng Hospital
Shanghai, Shanghai Municipality, 200003, China
Location status: Recruiting
Location contact
Tuo Dr. Li, Vice Professor
CONTACT
Tuo Li, MD
PRINCIPAL_INVESTIGATOR
Yongquan Shi, MD
PRINCIPAL_INVESTIGATOR
CONTACT
NCT Number: NCT06590220
Thyroid-associated ophthalmopathy (TAO) is an organ-specific autoimmune disease closely related to thyroid disease, which leads the incidence of orbital disease in adults and is the most common cause of diffuse toxic goiter (Graves disease, GD). The clinical manifestations of TAO are complex and varied. In severe cases, it may seriously impair visual function, affect daily life, and even cause corneal ulceration, perforation, and blindness. Therefore, a reasonable and effective treatment plan should be chosen according to the degree of TAO.
The aim of this clinical study is to:
1. Found the new diagnostic markers or imaging sequences. 2. Establish and validate a multimodal and multiparameter prediction model for moderate to severe TAO.
Interested in participating?
Request Info18 year–80 year
All sexes
Observational
Shanghai, Shanghai Municipality, 200003, China
Location status: Recruiting
Tuo Dr. Li, Vice Professor
CONTACT
Tuo Li, MD
PRINCIPAL_INVESTIGATOR
Yongquan Shi, MD
PRINCIPAL_INVESTIGATOR
CONTACT
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: 1 week after the end of treatment
Time frame: 24 weeks after the end of treatment
Time frame: 52 weeks after the end of treatment
Time frame: 104 weeks after the end of treatment
Time frame: 1 week after the end of treatment
Safety and Tolerability
Time frame: 104 weeks after the end of treatment
including TG(mmol/L)、TC(mmol/L)、HDL(mmol/L)、LDL(mmol/L)
Time frame: 104 weeks after the end of treatment
including T3(nmol/L)、T4(nmol/L)
Time frame: 104 weeks after the end of treatment
including TSH(mIU/L)
Time frame: 104 weeks after the end of treatment
including FT3(pmol/L)、FT4(pmol/L)
Time frame: 104 weeks after the end of treatment
including TRAb(IU/l)
Time frame: 104 weeks after the end of treatment
Time frame: 1 week after the end of treatment
including CD3(%)、CD3 absolute value、CD4(%)、CD4 absolute value、CD8(%)、CD8 absolute value、CD4/CD8(%)
Time frame: 104 weeks after the end of treatment
including CD3(%)、CD3 absolute value、CD4(%)、CD4 absolute value、CD8(%)、CD8 absolute value、CD4/CD8(%)
Time frame: 4 weeks after the end of treatment
Contact information is provided by the study sponsor or research team.
Shanghai Changzheng Hospital
Other
Establishment of Multiparametric Prediction Models for Moderate to Severe Thyroid Associated Ophthalmopathy
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07124572
Autoimmune Diseases, Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Hangzhou, Zhejiang, China
View Trial DetailsNCT06112340
Autoimmune Diseases, Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Miami, Florida, United States
View Trial DetailsNCT06392906
Autoimmune Diseases, Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Bangkok Noi, Thailand
View Trial DetailsNCT03131726
Autoimmune Diseases, Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Malmö, Sweden
View Trial Details